Work

Outcomes and safety analysis of a phase IB trial of stereotactic body radiotherapy (SBRT) to all sites of oligometastatic non-small cell lung cancer combined with durvalumab and tremelimumab.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.e21212

Authors: Michael Frederick Bassetti, Nan Sethakorn, Joshua Michael Lang, Jennifer L. Schehr, Zachery Schultz, Zachary Scott Morris, Kristina A. Matkowskyj, Jens C. Eickhoff, Brett Morris, Anne M. Traynor, Narjust Duma, Toby Christopher Campbell, Andrew Baschnagel, Ticiana Leal

Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, UW Health University Hospital, Mayo Clinic

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3169747180

Cites:

Cited by: 3

Related to: 10